Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70017 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Yu Zhai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Severe Fever with Thrombocytopenia Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Intravenous immunoglobulin (IVIG) is frequently administered to patients with severe fever with thrombocytopenia syndrome (SFTS), particularly those with severe manifestations, although its efficacy remains controversial. The study retrospectively analyzed the effects of IVIG administration on SFTS patients in both mild and severe groups. The primary outcome measure was 28‐day mortality. Inverse probability of treatment weighting (IPTW) with propensity score was used to account for baseline confounders. A total of SFTS patients with complete data enrolled from January 1, 2015, to August 1, 2023. Death at 28 days occurred for 68 (17.5%) patients. By unadjusted analysis, no difference was observed for 28‐day mortality between the IVIG and non‐IVIG groups in both the mild and severe groups. Similar results were found by propensity score matching and by IPTW analysis. Although IVIG is frequently used as adjuvant therapy for severe SFTS patients, no significant association was observed between IVIG treatment and reduced mortality in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Nanjing, China.
- Department of Emergency Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Pharmacy, Nanjing Drum Tower Hospital, School of Pharmacy, Nanjing Medical University, Nanjing, China.
- Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
ORCID-Profile: Haopeng Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhai, Y., Li, H., Xia, P., Jiang, Y., Tong, H., Zhou, D., Jiang, C., Liu, Y., & Wang, J. (2024). Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70017
Vancouver
Zhai Y, Li H, Xia P, Jiang Y, Tong H, Zhou D, et al. Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study. Journal of Medical Virology. 2024. doi:10.1002/jmv.70017
BibTeX
@article{Zhai2024,
author = {Zhai, Yu and Li, Haopeng and Xia, Peng and Jiang, Yunfei and Tong, Hanwen and Zhou, Dongming and Jiang, Chenxiao and Liu, Yun and Wang, Jun},
title = {Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70017}
}
EUVIMED